Astera Labs (NASDAQ:ALAB) Given New $225.00 Price Target at Roth Capital

Astera Labs (NASDAQ:ALAB) had its target price boosted by equities research analysts at Roth Capital from $200.00 to $225.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Roth Capital’s target price indicates a potential upside of 24.42% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Evercore ISI raised their target price on Astera Labs from $104.00 to $215.00 and gave the company an “outperform” rating in a report on Wednesday, August 6th. Northland Capmk downgraded Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 22nd. Cowen reaffirmed a “hold” rating on shares of Astera Labs in a report on Wednesday. Morgan Stanley raised their target price on Astera Labs from $155.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, August 29th. Finally, JPMorgan Chase & Co. raised their target price on Astera Labs from $180.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday. Thirteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $181.00.

Astera Labs Stock Up 0.9%

Shares of Astera Labs stock traded up $1.53 during trading on Wednesday, reaching $180.84. The company’s stock had a trading volume of 5,320,802 shares, compared to its average volume of 5,236,680. The business’s 50-day moving average price is $196.79 and its 200-day moving average price is $138.70. The firm has a market cap of $30.06 billion, a PE ratio of 321.74, a P/E/G ratio of 4.70 and a beta of 1.37. Astera Labs has a 52 week low of $47.13 and a 52 week high of $262.90.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.10. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The firm had revenue of $230.58 million for the quarter, compared to analyst estimates of $206.42 million. During the same quarter last year, the company earned $0.23 EPS. The company’s revenue was up 103.9% on a year-over-year basis. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Equities analysts predict that Astera Labs will post 0.34 earnings per share for the current year.

Insider Activity at Astera Labs

In related news, CFO Michael Truett Tate sold 18,861 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $183.51, for a total transaction of $3,461,182.11. Following the sale, the chief financial officer owned 259,512 shares of the company’s stock, valued at $47,623,047.12. This trade represents a 6.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Manuel Alba sold 183,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $173.27, for a total value of $31,708,410.00. Following the sale, the director directly owned 385,863 shares in the company, valued at approximately $66,858,482.01. This trade represents a 32.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,092,997 shares of company stock worth $192,231,120 over the last 90 days. 12.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Oliver Lagore Vanvalin Investment Group acquired a new position in Astera Labs during the 2nd quarter worth about $29,000. Bernard Wealth Management Corp. acquired a new position in Astera Labs during the 2nd quarter worth about $36,000. Clearstead Trust LLC lifted its holdings in Astera Labs by 46,100.0% during the 2nd quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock worth $42,000 after buying an additional 461 shares during the period. Advisors Asset Management Inc. lifted its holdings in Astera Labs by 68.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after buying an additional 194 shares during the period. Finally, Manchester Capital Management LLC lifted its holdings in Astera Labs by 141.5% during the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after buying an additional 283 shares during the period. 60.47% of the stock is owned by institutional investors and hedge funds.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.